With the July 2024 Prescription Drug User Fee Act (PDUFA) target action date for roflumilast cream, 0.15% in atopic dermatitis (AD) drawing near, Melissa Gooderham, MSc, MD, FRCPC, Medical Director at the SKiN Centre for Dermatology in Peterborough, Ontario, Canada, shares new data from the INTEGUMENT-OLE long-term, open-label study of roflumilast cream, 0.15% for the treatment of mild to moderate AD in adults and children down to age 6 showing that roflumilast cream was effective and well-tolerated, with no new safety signals observed up to 56 weeks of treatment.
